Literature DB >> 9356498

Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

J Levitskaya1, A Sharipo, A Leonchiks, A Ciechanover, M G Masucci.   

Abstract

The Epstein-Barr virus (EBV) encoded nuclear antigen (EBNA) 1 is expressed in latently infected B lymphocytes that persist for life in healthy virus carriers and is the only viral protein regularly detected in all EBV associated malignancies. The Gly-Ala repeat domain of EBNA1 was shown to inhibit in cis the presentation of major histocompatibility complex (MHC) class I restricted cytotoxic T cell epitopes from EBNA4. It appears that the majority of antigens presented via the MHC I pathway are subject to ATP-dependent ubiquitination and degradation by the proteasome. We have investigated the influence of the repeat on this process by comparing the degradation of EBNA1, EBNA4, and Gly-Ala containing EBNA4 chimeras in a cell-free system. EBNA4 was efficiently degraded in an ATP/ubiquitin/proteasome-dependent fashion whereas EBNA1 was resistant to degradation. Processing of EBNA1 was restored by deletion of the Gly-Ala domain whereas insertion of Gly-Ala repeats of various lengths and in different positions prevented the degradation of EBNA4 without appreciable effect on ubiquitination. Inhibition was also achieved by insertion of a Pro-Ala coding sequence. The results suggest that the repeat may affect MHC I restricted responses by inhibiting antigen processing via the ubiquitin/proteasome pathway. The presence of regularly interspersed Ala residues appears to be important for the effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356498      PMCID: PMC25057          DOI: 10.1073/pnas.94.23.12616

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis.

Authors:  K Falk; J W Gratama; M Rowe; J Z Zou; F Khanim; L S Young; M A Oosterveer; I Ernberg
Journal:  J Gen Virol       Date:  1995-04       Impact factor: 3.891

2.  Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane.

Authors:  S Zhang; T Holmes; C Lockshin; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

3.  Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

Authors:  J Levitskaya; M Coram; V Levitsky; S Imreh; P M Steigerwald-Mullen; G Klein; M G Kurilla; M G Masucci
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

4.  A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation.

Authors:  M T Michalek; E P Grant; C Gramm; A L Goldberg; K L Rock
Journal:  Nature       Date:  1993-06-10       Impact factor: 49.962

5.  Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure.

Authors:  M R Chen; J M Middeldorp; S D Hayward
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

Review 6.  The ubiquitin-proteasome proteolytic pathway.

Authors:  A Ciechanover
Journal:  Cell       Date:  1994-10-07       Impact factor: 41.582

7.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.

Authors:  K L Rock; C Gramm; L Rothstein; K Clark; R Stein; L Dick; D Hwang; A L Goldberg
Journal:  Cell       Date:  1994-09-09       Impact factor: 41.582

Review 8.  Epstein-Barr virus: adaptation to a life within the immune system.

Authors:  M G Masucci; I Ernberg
Journal:  Trends Microbiol       Date:  1994-04       Impact factor: 17.079

9.  Stress resistance in Saccharomyces cerevisiae is strongly correlated with assembly of a novel type of multiubiquitin chain.

Authors:  T Arnason; M J Ellison
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.

Authors:  R Khanna; S R Burrows; M G Kurilla; C A Jacob; I S Misko; T B Sculley; E Kieff; D J Moss
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  165 in total

Review 1.  Aggresomes and Russell bodies. Symptoms of cellular indigestion?

Authors:  R R Kopito; R Sitia
Journal:  EMBO Rep       Date:  2000-09       Impact factor: 8.807

2.  Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.

Authors:  N W Blake; A Moghaddam; P Rao; A Kaur; R Glickman; Y G Cho; A Marchini; T Haigh; R P Johnson; A B Rickinson; F Wang
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

4.  An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency.

Authors:  B T Tan; L Wu; A J Berk
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells.

Authors:  J I Cohen; K Lekstrom
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency.

Authors:  M G Davenport; J S Pagano
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus.

Authors:  M A Lee; M E Diamond; J L Yates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.

Authors:  P Steigerwald-Mullen; M G Kurilla; T J Braciale
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

9.  Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.

Authors:  Stijn Heessen; Ainars Leonchiks; Natalia Issaeva; Anatoly Sharipo; Galina Selivanova; Maria G Masucci; Nico P Dantuma
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

10.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.